Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
NCT ID: NCT00044564
Last Updated: 2014-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
54 participants
INTERVENTIONAL
2001-12-31
2003-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Bay 59-8862
75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bay 59-8862
75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Jolla, California, United States
Muncie, Indiana, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Greenbelt, Maryland, United States
Detroit, Michigan, United States
Southfield, Michigan, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
New Brunswick, New Jersey, United States
Salt Lake City, Utah, United States
Milwaukee, Wisconsin, United States
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Greater Sudbury, Ontario, Canada
Caen, , France
Montpellier, , France
Heidelberg, Baden-Wurttemberg, Germany
Tübingen, Baden-Wurttemberg, Germany
München, Bavaria, Germany
München, Bavaria, Germany
Düsseldorf, North Rhine-Westphalia, Germany
Münster, North Rhine-Westphalia, Germany
Rotterdam, , Netherlands
Plymouth, Devon, United Kingdom
Manchester, Greater Manchester, United Kingdom
Cardiff, South Glamorgan, United Kingdom
Sutton, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
100386
Identifier Type: -
Identifier Source: org_study_id